Test in Focus
In this episode of “A Test in Focus,” Sanjeev Sethi, M.D., Ph.D., explains Mayo Clinic Laboratories’ new immunohistochemistry assay for the detection of NELL-1 antigen, a biomarker for membranous nephropathy (MN). Identified by Dr. Sethi in 2019, NELL-1 antigen triggers the production of NELL-1 antibodies, which are present in approximately 10% to 15% of MN patients and may be associated with an underlying cancer.
“While many cases of NELL-1 are primary and there’s no disease association, there are multiple studies now that show a subset of NELL-1 positive patients have an underlying malignancy,” Dr. Sethi says. “So if a physician gets a diagnosis of NELL-1 membranous nephropathy, they need to be extra vigilant in screening for hidden malignancies, because it is possible that you treat the malignancy and then the membranous goes away as well.”
Dr. Sethi notes that establishing disease etiology through NELL-1 antigen detection not only enables accurate diagnosis, but elevates treatment outcomes by providing a disease expression on which to base follow-up care.
Listen to learn more about how NELL-1 antigen testing enhances MN diagnosis by equipping providers with specific information on disease manifestation.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
NELL1 | Neural Epidermal Growth Factor-Like 1 Protein Immunostain, Technical Component Only (coming soon)
Identification of neural epidermal growth factor-like 1 protein (NELL1) primary membranous nephropathy
Zhiyv (Neal) Niu, Ph.D., and Rodolfo Savica, M.D., Ph.D., explain why Mayo Clinic Laboratories' gene panel is the most comprehensive test available for inherited Parkinson's disease. The new panel covers all mutations known to cause the condition — or increase the risk of developing it.
Zhiyv (Neal) Niu, Ph.D., and Christopher Klein, M.D., explain how Mayo Clinic Laboratories' updated neuromuscular gene panel informs diagnosis and treatment. The phenotype-based panel covers the complete list of neuromuscular genes and their variants.